Madrigal's First Full Quarter of Rezdiffra Sales With Nowhere Left to Hide

Madrigal Pharmaceuticals (MDGL) reports first-quarter 2026 earnings before the market opens on May 6, 2026, with investors focused on the commercial trajectory of resmetirom (Rezdiffra), the company's recently approved treatment for metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis. After a volatile earnings track record—including a massive miss last quarter—the central question is whether MDGL can demonstrate sustainable prescription growth and a credible path to profitability as it scales its first commercial product.

Part 1: Earnings Preview

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company that recently transitioned to commercialization with the FDA approval of resmetirom, a once-daily oral thyroid hormone receptor-β agonist for MASH with liver fibrosis. The company's prospects now hinge on successful commercial execution, payer coverage expansion, and patient uptake of its lead asset.

MDGL is expected to report first-quarter 2026 results before the open on May 6, 2026, with the consensus estimate calling for a loss of $3.61 per share on revenue of approximately $301.07 million. The company most recently reported fourth-quarter 2025 earnings of -$2.57 per share, missing estimates by a staggering 6,525%. Year-over-year, the consensus estimate represents a -8.73% decline compared to the -$3.32 per share loss reported in the first quarter of 2025, reflecting continued investment in the commercial launch.

Three key themes define this earnings story:

1. Commercial Launch Momentum: Investors will scrutinize prescription trends, sales velocity, and sequential revenue growth for resmetirom. With Q4 2025 revenue reaching $321.08 million—up 210.8% year-over-year—the critical question is whether MDGL can sustain or accelerate that growth trajectory. Any signs of slowing demand or distribution challenges could weigh heavily on the stock.

2. Path to Profitability: The consensus now expects MDGL to swing to $12.45 per share in earnings for 2027, representing a dramatic +326.78% improvement from 2026's projected -$5.49 loss. Investors will look for management commentary on operating leverage, gross margins, and the timeline to positive cash flow as the launch matures.

3. Payer Coverage and Market Access: Reimbursement dynamics remain critical. Analysts are watching for updates on formulary wins, prior authorization hurdles, and patient access metrics. Broader payer adoption could unlock significant upside, while coverage setbacks could delay the path to profitability.

Leading analysts remain overwhelmingly bullish despite recent volatility. Bank of America recently initiated coverage with an "overweight" rating and a $964 price target, citing resmetirom's blockbuster potential. However, the firm also cautioned that execution risk remains elevated during the early commercial phase. Barclays echoed this optimism, highlighting the large addressable MASH patient population and limited competition in the near term. Analysts are particularly focused on whether MDGL can demonstrate consistent quarter-over-quarter prescription growth and provide visibility into the 2027 profitability outlook.

Part 2: Historical Earnings Performance

Madrigal Pharmaceuticals has delivered a highly inconsistent earnings track record over the past four quarters, with dramatic swings between beats and misses. In Q1 2025, the company reported -$3.32 per share against an estimate of -$3.62, delivering a modest +8.29% beat. The following quarter (Q2 2025) saw a much larger upside surprise, with actual EPS of -$1.90 versus expectations of -$3.48, a +45.40% beat that reflected better-than-expected early commercial traction for resmetirom.

However, the second half of 2025 brought significant volatility. Q3 2025 produced a massive -156.57% miss, with reported EPS of -$5.08 far worse than the -$1.98 estimate, likely driven by elevated launch-related expenses. The most recent quarter (Q4 2025) delivered an even more extreme disappointment: MDGL reported -$2.57 per share against a consensus estimate of +$0.04, a staggering -6,525% miss that shocked investors and triggered an -11.11% single-day decline.

The pattern reveals a company in transition from clinical development to commercialization, with earnings heavily influenced by the timing of launch investments, manufacturing scale-up costs, and revenue recognition dynamics. The wide variance between estimates and actuals suggests analysts are still calibrating their models to the company's new commercial reality, making this quarter's results particularly difficult to predict.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Madrigal Pharmaceuticals typically reports earnings before the market open, meaning Day 0 reflects the first full trading session where investors can react to results, while Day +1 captures follow-through momentum.

Historical price action around MDGL earnings has been highly volatile, with an average absolute Day 0 move of 10.52% and an average Day +1 move of 6.12%. The most dramatic recent reaction came after the October 2024 report, when the stock surged +20.10% on Day 0 and extended gains by another +23.23% on Day +1, reflecting strong early commercial data. Conversely, the February 2026 report (most recent) triggered an -11.11% Day 0 decline following the massive earnings miss.

The data shows MDGL tends to experience larger intraday volatility on earnings day (average range of 10.89%) than on the following session (average range of 8.84%), suggesting initial reactions are often sharp but can moderate as investors digest the details. Positive surprises have historically driven sustained multi-day rallies, while disappointments tend to produce immediate sharp selloffs with more muted follow-through. Given the stock's recent volatility and the uncertainty around commercial execution, investors should prepare for a potentially significant move in either direction.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of ±9.18% (±$46.14) for the May 15, 2026 expiration, which is slightly below the stock's average historical Day 0 move of 10.52% but above the average Day +1 move of 6.12%. This suggests options traders are anticipating meaningful volatility but perhaps less extreme than some of the recent post-earnings swings, particularly the +20.10% and -11.11% moves seen in the past year.

Part 3: What Analysts Are Saying

Analyst sentiment on Madrigal Pharmaceuticals remains strongly bullish, with the consensus rating at 4.68 out of 5.0—firmly in "Strong Buy" territory. The current breakdown shows 16 Strong Buy ratings, 0 Moderate Buys, 3 Holds, and 0 Sells, reflecting overwhelming confidence in the company's long-term commercial potential despite recent earnings volatility. The average price target of $658.12 implies +31.0% upside from the current price of $502.47, with a high target of $964.00 suggesting some analysts see potential for nearly doubling from current levels.

Sentiment has remained unchanged over the past month, with the rating distribution and average recommendation holding steady at 4.68. This stability is notable given the dramatic Q4 2025 earnings miss in February, suggesting analysts are looking through near-term execution noise and focusing on the longer-term revenue ramp and path to profitability. The tight clustering of ratings—with no sell-side recommendations—indicates broad agreement that resmetirom's commercial opportunity justifies the current valuation, even as the company navigates the challenges of scaling a first-in-class therapy.

The $658.12 consensus target sits well above the current price, implying analysts expect the stock to re-rate higher as MDGL demonstrates consistent revenue growth and moves closer to breakeven. However, the wide range between the low target of $533.00 and the high of $964.00 reflects meaningful uncertainty around the pace of commercial adoption and the timeline to profitability.

Part 4: Technical Picture

The Barchart Technical Opinion for MDGL currently stands at 40% Buy, down from 56% Buy both one week ago and one month ago, signaling deteriorating near-term momentum heading into the earnings release. This weakening technical picture reflects the stock's recent pullback from higher levels and suggests caution among momentum-driven traders.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal indicates near-term momentum is mixed, with the stock consolidating after recent volatility
• Medium-term (Hold): Neutral reading suggests the intermediate-term trend has stalled as investors await clarity on commercial execution
• Long-term (50% Buy): Moderate buy signal reflects underlying strength in the longer-term trend despite recent choppiness

Trend Characteristics: The current trend is characterized as Weak in strength and in the Weakest direction, indicating the stock is struggling to maintain upward momentum and faces headwinds heading into the earnings event.

The stock is currently trading at $502.47, positioned below its 5-day ($514.16), 10-day ($516.79), 20-day ($520.62), and 100-day ($503.32) moving averages, but above its 50-day ($485.43) and 200-day ($470.85) moving averages.

This mixed technical setup—with the stock below short-term moving averages but above longer-term support—suggests MDGL is in a consolidation phase heading into earnings. The deteriorating Barchart Opinion and weak trend characteristics indicate near-term momentum has stalled, which could amplify downside risk if results disappoint. However, the stock's position above the 200-day moving average provides a technical floor, and a strong earnings beat could quickly reverse the recent weakness and propel MDGL back toward the $520–$550 range. Given the high implied volatility and recent earnings history, traders should expect a decisive move in either direction, with technical levels likely to be overwhelmed by the fundamental reaction to commercial execution metrics.